Sodium succinate dibasic hexahydrate
CAS: 6106-21-4
Ref. 3D-GAA10621
1kg | Descatalogado | ||
2kg | Descatalogado | ||
5kg | Descatalogado | ||
100g | Descatalogado | ||
10kg | Descatalogado | ||
250g | Descatalogado | ||
25kg | Descatalogado | ||
500g | Descatalogado |
Información del producto
- Butanedioate, Sodium Salt, Hydrate (1:1:6)
- Butanedioic Acid Disodium Salt Hexahydrate
- Butanedioic acid, sodium salt, hydrate (1:2:6)
- Di-Sodium Succinate Hexahydrate
- Disodium Butanedioate Hexahydrate
- Disodium Succinate, Hexahydrate
- Fema 3277
- Methyl 2-[(2-Chloro-4-Nitrobenzoyl)Amino]-4,5,6,7,8,9-Hexahydrocycloocta[B]Thiophene-3-Carboxylate
- Sodium Succinate 6-Hydrate
- Sodium Succinate Dibasic Hexahydrate
- Ver más sinónimos
- Sodium Succinate Hexahydrate
- Succinic Acid, Disodium Salt, 6-Hydrate
- Succinic acid, disodium salt, hexahydrate
- Succinic Acid Disodium Salt Hexahydrate
Sodium succinate dibasic hexahydrate is an enzyme activator that helps to maintain healthy bowel function. It is a salt of sodium succinate and dibasic sodium phosphate. The product is used in the treatment of bowel disease, including inflammatory bowel disease, ulcerative colitis, and Crohn's disease. This drug binds to copper ions and inhibits their activity in the mitochondria, which may be helpful in the treatment of mitochondrial diseases. Sodium succinate dibasic hexahydrate has also been shown to have antioxidant properties that may be helpful for autoimmune diseases. The safety of this product has not been studied extensively; however, it does not appear to cause any toxicity when administered orally or intravenously.